Raymond James Financial Services Advisors’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $69.7K | Buy |
+12,275
| New | +$70.8K | ﹤0.01% | 3337 |
|
|
2023
Q4 | – | Sell |
-31,155
| Closed | -$204K | – | 3309 |
|
|
2023
Q3 | $204K | Sell |
31,155
-2,165
| -6% | -$17.2K | ﹤0.01% | 2923 |
|
|
2023
Q2 | $271K | Buy |
33,320
+1,300
| +4% | +$11.1K | ﹤0.01% | 2730 |
|
|
2023
Q1 | $274K | Sell |
32,020
-46
| -0.1% | -$459 | ﹤0.01% | 2707 |
|
|
2022
Q4 | $297K | Buy |
32,066
+1,796
| +6% | +$19.2K | ﹤0.01% | 2589 |
|
|
2022
Q3 | $312K | Buy |
30,270
+2,500
| +9% | +$26.4K | ﹤0.01% | 2543 |
|
|
2022
Q2 | $278K | Buy |
27,770
+2,000
| +8% | +$18.9K | ﹤0.01% | 2642 |
|
|
2022
Q1 | $317K | Buy |
25,770
+1,561
| +6% | +$19.2K | ﹤0.01% | 2675 |
|
|
2021
Q4 | $420K | Buy |
24,209
+1,000
| +4% | +$19K | ﹤0.01% | 2487 |
|
|
2021
Q3 | $417K | Sell |
23,209
-35,362
| -60% | -$704K | ﹤0.01% | 2481 |
|
|
2021
Q2 | $1.34M | Buy |
58,571
+2,644
| +5% | +$39.2K | ﹤0.01% | 1741 |
|
|
2021
Q1 | $836K | Sell |
55,927
-6,493
| -10% | -$70.9K | ﹤0.01% | 1971 |
|
|
2020
Q4 | $337K | Buy |
62,420
+15,000
| +32% | +$79K | ﹤0.01% | 2396 |
|
|
2020
Q3 | $216K | Buy |
47,420
+11,000
| +30% | +$47.3K | ﹤0.01% | 2494 |
|
|
2020
Q2 | $179K | Sell |
36,420
-2,830
| -7% | -$10.7K | ﹤0.01% | 2526 |
|
|
2020
Q1 | $124K | Buy |
39,250
+20,000
| +104% | +$69.7K | ﹤0.01% | 2192 |
|
|
2019
Q4 | $50K | Hold |
19,250
| – | – | ﹤0.01% | 2760 |
|
|
2019
Q3 | $61K | Sell |
19,250
-1,500
| -7% | -$4.33K | ﹤0.01% | 2690 |
|
|
2019
Q2 | $70K | Buy |
20,750
+5,500
| +36% | +$17.1K | ﹤0.01% | 2718 |
|
|
2019
Q1 | $47K | Hold |
15,250
| – | – | ﹤0.01% | 2708 |
|
|
2018
Q4 | $24K | Hold |
15,250
| – | – | ﹤0.01% | 2506 |
|
|
2018
Q3 | $42K | Buy |
+15,250
| New | +$43K | ﹤0.01% | 2726 |
|
Other funds holding AVXL
NL
